Phase 3 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who are able to give informed consent (agree to participate after being told what the study involves)
- People whose main diagnosis is a fast, irregular heartbeat called atrial fibrillation or atrial flutter, with a heart rate of 120 beats per minute or higher
- People being treated with a medication called diltiazem to help slow their heart rate
- People who speak English
Who may not be able to join:
- People whose blood pressure is dangerously low (confirm with trial site for specific numbers)
- People who are not fully conscious or aware
- People with severe kidney failure who require dialysis (either hemodialysis or peritoneal dialysis)
- People experiencing a sudden worsening of heart failure, as determined by a doctor's assessment and/or imaging
- People whose fast heart rate is thought by medical staff to be the body's response to a different underlying condition
- People with heart rhythm problems other than atrial fibrillation or atrial flutter, such as sick sinus syndrome or certain abnormal electrical patterns in the heart
- People having a heart attack at the time of the trial
- People who are pregnant, based on a positive pregnancy test
- People who have a medical reason they cannot receive magnesium sulfate, including a condition called myasthenia gravis
- People who have a known allergy or sensitivity to any of the medications used in the study
- People who have already taken part in this trial at a previous visit
- People who have previously withdrawn from this study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Travis Hase, MD, Wake Forest University Health Sciences
Phone: (708) 684-1078
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Ventricular rate control
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.